Yamanouchi/Fujisawa Merger: Closing Japanese Options
Executive Summary
The Yamanouchi/Fujisawa acquisition may be the most important transaction to have occured in Japan in decades--or will be if it goes through. One key element: the deal ends important merger options for mid-size Japanese companies, who had more or less closed off transaction possibilities with Western companies at least partly in the hope of being able to do an intra-Japan deal. Now the Western firms have decided to build their own Japanese infrastructure, leaving the mid-sized firms without the strategic flexibility they once thought they had.
You may also be interested in...
Theravance/Astellas: Quality Deal but without the Brand Name
Branding works--in packaged goods and among investors. That's why, rather than taking Theravance's rich marketing deal with the Japanese company Astellas for the antibiotic telavancin -- rich in comparison to the best licensing deals signed in the segment -- as a net positive for the company, shareholders seemed disappointed.
Deal Statistics Quarterly, Q4 2004
In this issue, we present another installment of our quarterly review of dealmaking-for October-December 2004. Our data comes from Windhover's Strategic Transactions Database, which covers deal activity within the pharmaceutical/biotechnology, medical device, and in vitro diagnostics industries.
Deal Statistics Quarterly, Q4 2004
In this issue, we present another installment of our quarterly review of dealmaking-for October-December 2004. Our data comes from Windhover's Strategic Transactions Database, which covers deal activity within the pharmaceutical/biotechnology, medical device, and in vitro diagnostics industries.